Interleukin-2-Fc fusion proteins and methods of use

Provided are serum half-life extended-IL-2 variant (IL-2v) heterodimers having reduced binding to the IL2R[alpha] (CD25) subunit. In particular, Fc-IL-2v heterodimers are provided and methods for making and using, e.g. for enhancing an immune response, e.g. in the prevention and treatment of viral i...

Full description

Saved in:
Bibliographic Details
Main Authors HUNG, MAGDELEINE S, NAGEL, MARK R, TAM, DANNY W, KHAN, SHAHZADA, MUKHERJEE, PRASENJIT K, JAVANBAKHT, HASSAN, THOMAS, MAJLINDA K, BACA, MANUEL, GILMORE, SARAH A, KANWAR, MANU, PAPALIA, GIUSEPPE
Format Patent
LanguageChinese
English
Published 01.07.2022
Subjects
BEER
BIOCHEMISTRY
CHEMISTRY
COMPOSITIONS THEREOF
CULTURE MEDIA
ENZYMOLOGY
HUMAN NECESSITIES
HYGIENE
MEDICAL OR VETERINARY SCIENCE
METALLURGY
MICROBIOLOGY
MICROORGANISMS OR ENZYMES
MUTATION OR GENETIC ENGINEERING
ORGANIC CHEMISTRY
PEPTIDES
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS
SPIRITS
VINEGAR
WINE
Online AccessGet full text

Cover

More Information
Summary:Provided are serum half-life extended-IL-2 variant (IL-2v) heterodimers having reduced binding to the IL2R[alpha] (CD25) subunit. In particular, Fc-IL-2v heterodimers are provided and methods for making and using, e.g. for enhancing an immune response, e.g. in the prevention and treatment of viral infections and cancer.
Bibliography:Application Number: TW202110137881